This open label, non-randomized, prospective phase I study is designed to evaluate if the
addition of natural killer cell therapy (KDS-1001) to tyrosine kinase inhibitors (TKIs) for
chronic myeloid leukemia (CML) patients with persistent or recurrent molecular residual
disease (MRD) after at least one year of TKI therapy will allow patients to achieve RT-PCR
negativity (MRD negative). This may have implications for future TKI cessation studies.